We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

107 hedge funds and large institutions have $120M invested in Corbus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

740% more call options, than puts

Call options by funds: $3.94M | Put options by funds: $469K

85% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 13

50% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 22

12% more capital invested

Capital invested by funds: $108M → $120M (+$12.6M)

7% more funds holding

Funds holding: 100 → 107 (+7)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.12% less ownership

Funds ownership: 75.45% → 72.33% (-3.1%)

Holders
107
Holders Change
+7
Holders Change %
+7%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
33
Reduced
22
Closed
13
Calls
$3.94M
Puts
$469K
Net Calls
+$3.47M
Net Calls Change
+$2.96M

Top Buyers

Rank Fund Capital Flow
1
DP
Diadema Partners
New Jersey
+$3.7M
2
O
OrbiMed
New York
+$1.18M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$889K
4
PAP
Persistent Asset Partners
Hong Kong
+$881K
5
EAM
Exome Asset Management
New York
+$796K

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$7.77M
2
AC
Armistice Capital
New York
-$1.45M
3
Ameriprise
Ameriprise
Minnesota
-$1.1M
4
Citadel Advisors
Citadel Advisors
Florida
-$978K
5
HP
HealthInvest Partners
Sweden
-$873K
Name Holding Trade Value Shares
Change 		Change in
Stake
Assenagon Asset Management
26
Assenagon Asset Management
Luxembourg
$800K -$865K -102,710 -55%
Jane Street
27
Jane Street
New York
$687K +$380K +45,129 +161%
State Street
28
State Street
Massachusetts
$647K +$116K +13,780 +25%
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$612K -$573K -68,110 -51%
Simplex Trading
30
Simplex Trading
Illinois
$496K +$445K +52,836 New
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$482K -$201K -23,838 -32%
PCM
32
Prelude Capital Management
New York
$477K +$278K +33,045 +186%
VA
33
Verdad Advisers
Massachusetts
$472K +$423K +50,252 New
RC
34
Rangeley Capital
Connecticut
$421K +$378K +44,840 New
Northern Trust
35
Northern Trust
Illinois
$390K -$1.6K -190 -0.5%
CF
36
Cantor Fitzgerald
New York
$377K +$338K +40,098 New
UBS Group
37
UBS Group
Switzerland
$363K -$106K -12,571 -25%
XT
38
XTX Topco
Cayman Islands
$357K +$320K +38,023 New
Morgan Stanley
39
Morgan Stanley
New York
$308K +$88.2K +10,473 +47%
BHCM
40
Brevan Howard Capital Management
Jersey
$307K +$117K +13,884 +74%
JF
41
Jump Financial
Illinois
$287K -$250K -29,700 -49%
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$281K +$113K +13,401 +81%
Hudson Bay Capital Management
43
Hudson Bay Capital Management
Connecticut
$278K +$105K +12,489 +73%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$249K -$19.5K -2,320 -8%
VCIM
45
Velan Capital Investment Management
Georgia
$244K +$109K +13,000 +100%
VPM
46
Vanguard Portfolio Management
Pennsylvania
$229K +$205K +24,365 New
QC
47
Quadrature Capital
United Kingdom
$216K -$58.1K -6,903 -23%
ETC
48
Exchange Traded Concepts
Oklahoma
$208K +$186K +22,131 New
PFCS
49
Pale Fire Capital SE
Czech Republic
$200K +$22.7K +2,700 +14%
Barclays
50
Barclays
United Kingdom
$195K +$50.7K +6,024 +41%
1
2
3 4 5

CRBP Hedge Fund Activity: Q1 2026 in Review

107 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2026, worth a combined $120M — up 12% from $108M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CRBP positions and 13 closed out — a net gain of 11 holders — while 33 added to existing stakes and 22 trimmed.

The largest buyer was Diadema Partners, opening a new position worth an estimated $3.7M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.77M sold.

  • 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2026, up from 100 in Q4 2025.
  • Funds reported $120M of Corbus Pharmaceuticals stock for Q1 2026, up 12% quarter-over-quarter.
  • 24 funds opened new Corbus Pharmaceuticals positions in Q1 2026 and 13 closed out, a net change of +11 holders.
  • The largest Corbus Pharmaceuticals buyer in Q1 2026 was Diadema Partners, an estimated $3.7M added.
  • The largest Corbus Pharmaceuticals seller in Q1 2026 was Octagon Capital Advisors, an estimated $7.77M sold.

Based on aggregated 13F filings for Q1 2026.